Top of this page
Skip navigation, go straight to the content Newsroom Newsroom


Spotlight Story

UCB's Committment to Neurology

We recently announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

Read More


1  USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.


UCB U.S. News

 Jun 21, 2018

UCB Supports Georgia Bio Ed Institute Biotech Immersion Program

Read more
 Jun 20, 2018

“Mr. Researcher Goes to Washington” for GoBoldly

Read more
Jun 11, 2018

UCB and Rebuilding Together Help Fragility Fracture Patient Stay at …

Read more